← Back to Clinical Trials
Recruiting NCT05851768

NCT05851768 Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05851768
Status Recruiting
Phase
Sponsor National Cancer Institute, Egypt
Condition Analgesia
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-05-15
Primary Completion 2026-11-25

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
BupivacaineBupivacaine + MagnesiumBupivacaine + Dexmedetomidine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-05-15 with a primary completion date of 2026-11-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Postoperative pain management is considered an integral part of perioperative care in patients undergoing thoracotomy. In order to reduce these complications, multiple regional techniques have been developed for thoracotomy including Intercostal nerve block, Erectospinae plane block and serratus block. Multiple adjuvants have been used in regional analgesia including adrenaline,clonidine,magnesium sulphate,dexmedatomidine and opoids.

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 65 years. * Male and female sexes. * ASA I-II.,III * Cancer patients undergoing thoracotomy incisions * Body mass index (BMI) from 18.5 to 30 kg/m2 Exclusion Criteria: * Patient refusal * Known allergy to any of the used drugs * Low platelet count, any coagulation defect

Contact & Investigator

Central Contact

Walaa Y Elsabeeny, MD

✉ walaa.elsabeeny@nci.cu.edu.eg

📞 01007798466

Principal Investigator

Walaa Y Elsabeeny, MD

PRINCIPAL INVESTIGATOR

Assistant professor of Anesthesia and Pain Management, National Cancer Institute, Cairo University

Frequently Asked Questions

Who can join the NCT05851768 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05851768 currently recruiting?

Yes, NCT05851768 is actively recruiting participants. Contact the research team at walaa.elsabeeny@nci.cu.edu.eg for enrollment information.

Where is the NCT05851768 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT05851768 clinical trial?

NCT05851768 is sponsored by National Cancer Institute, Egypt. The principal investigator is Walaa Y Elsabeeny, MD at Assistant professor of Anesthesia and Pain Management, National Cancer Institute, Cairo University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology